Sometimes, there are more important things to post than biotech deals. Our 6-year-old daughter, Griffen, wanted to help Ukrainian refugee children. She got to share her experience of how she helped 50+ children on CNN. We’re so proud of our little girl. https://t.co/WCTxsYTTMX
RT moderna_tx: We are committed to developing a portfolio of first-in-class mRNA vaccines against latent viruses. Latent viruses remain in the body for life after infection and can lead to chronic medical conditions.
RT moderna_tx: In addition to our #HIV vaccine candidates, we are working on vaccines against #CMV and #EBV and our research team is working to bring even more #mRNA vaccines against latent viruses to the clinic to improve human health.
RT moderna_tx: Respiratory viruses can cause illness and hospitalizations in young children and older adults. Our #mRNA vaccine program includes #vaccines against respiratory viruses where there is an unmet need.
RT moderna_tx: According to a study by the Institute for Health Metrics and Evaluation, how much money was spent globally on care, treatment, and prevention of HIV from 2010 to 2015?
RT moderna_tx: RT moderna_tx: #DidYouKnow that Esptein-Barr Virus (EBV) can lead to medical conditions other than mono, and is associated with an increas…
RT moderna_tx: ANNOUNCEMENT 📢: We are proud to announce that the first participant has been dosed in the Phase 1 study of mRNA-1644, our experimental #HIV#mRNA#vaccine candidate. Learn more about this exciting venture with IAVI: https://t.co/Xbx4h2Ki4r
RT moderna_tx: None of this would be possible without our partnerships, and we are grateful to gatesfoundation, scrippsresearch, UTSA, GWtweets, fredhutch, and EmoryUniversity.
RT moderna_tx: At six months after the third booster dose, Omicron neutralization had declined 6.3-fold from peak titers at day 29 post-boost, but remained detectable in all participants.
https://t.co/rFCGDPisyY
RT moderna_tx: Neutralizing titers against Omicron declined faster after the booster than for the wild-type virus (D614G) which declined 2.3-fold over the same time period.
RT moderna_tx: The objective of this extension of an earlier study will be to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 as a single #booster dose in adults aged 18 years and older in two cohorts. https://t.co/ym3gw3SKax
ANNOUNCEMENT 📢: Given the long-term threat demonstrated by Omicron’s immune escape, we are pleased to announce that the first participant has been dosed in the Phase 2 study of our #Omicron-specific #booster candidate (mRNA-1273.529)! Learn more: https://t.co/wtbRLWEBh9
RT moderna_tx: On January 8th, 2022, the Ambassador of Mexico to the United States emoctezumab, the Chief Officer for North America r_velascoa, and the Secretary of Education delfinagomeza, welcomed the arrival of the 2.7 million doses of #COVID19 vaccine donated by Moderna to Me
RT moderna_tx: This #BirthDefectsAwarenessMonth, learn more about Cytomegalovirus (CMV), which is the #1 infectious cause of birth defects in the United States. 91% of women have never heard of CMV, but together, we can change that.
RT moderna_tx: Awareness of birth defects #AcrossTheLifespan helps provide individuals, parents, & families with the information they need to seek proper care.
RT moderna_tx: #Cytomegalovirus (CMV) can be fatal to newborns. If you haven't been exposed to #CMV, please consider donating blood to help newborn babies who should only receive CMV negative blood transfusions as part of their medical care. #NBDM
RT moderna_tx: A new ScienceMagazine study reports that the risk of #MultipleSclerosis (MS) increased 32-fold after infection with #EpsteinBarr virus (EBV), and suggest EBV as the leading cause of MS.
https://t.co/SpSe5ESRYz
RT moderna_tx: mRNA-1189, our #EBV#vaccine candidate, is being developed to prevent EBV-induced infections and we recently announced that the first participant has been dosed in our Phase 1 study known as Eclipse.
https://t.co/6MOo8qNcLu
ANNOUNCEMENT 📢: We're proud to announce that the first participant has been dosed in the Phase 1 study of our Epstein-Barr Virus (#EBV) #mRNA#vaccine candidate. https://t.co/xczNmxp7Q9